Prostate Cancer clinical trials in Nevada

6 actively recruiting prostate cancer trials at 2 sites across Nevada.

Data from ClinicalTrials.gov · last refreshed 2026-10-12

Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03678025

Sites in Nevada:

Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Radiation Oncology Centers of Nevada Central — Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada - Northwest — Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada-Summerlin — Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06925737

Sites in Nevada:

Comprehensive Cancer Centers of Nevada ( Site 0082) — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Vitamin D for Prostate Endocrine Therapy

This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…

Sponsor: University of Rochester

NCT ID: NCT05838716

Sites in Nevada:

OptumCare Cancer Care at Charleston — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06136624

Sites in Nevada:

Comprehensive Cancer Centers of Nevada ( Site 0010) — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…

Sponsor: Candel Therapeutics, Inc.

NCT ID: NCT07332000

Sites in Nevada:

Sheldon Freedman, MD Ltd. — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis

NCT ID: NCT05176483

Sites in Nevada:

Exelixis Clinical Site #55 — Las Vegas, Nevada

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12